Combination meningitidis B/C vaccines

Details Combination meningitidis B/C vaccines Combination meningitidis B/C vaccines

2011-08-30

2011-08-30

Devi, S. (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Combination of antigens from multiple bacterial species

C424S197110, C424S250100, C424S184100, C424S234100, C424S236100, C424S831000, C424S832000

Reexamination Certificate

active

08007815

ABSTRACT:
Combination vaccines for treating or preventingNeisseria meningitidisinfection are described. The vaccines includeNeisseria meningitidisserogroup B proteoliposomic vesicles andNeissera meningitidisserogroup C conjugated oligosaccharides.

REFERENCES:
patent: 4707543 (1987-11-01), Zollinger et al.
patent: 5846735 (1998-12-01), Stapleton et al.
patent: 6180111 (2001-01-01), Stein et al.
patent: 6193971 (2001-02-01), Hofmann et al.
patent: 6355253 (2002-03-01), Zlotnick
patent: 6413520 (2002-07-01), Granoff
patent: 6451317 (2002-09-01), Blake et al.
patent: 6476201 (2002-11-01), Lowell et al.
patent: 6558677 (2003-05-01), Zollinger et al.
patent: 6638513 (2003-10-01), Seid
patent: 7018636 (2006-03-01), Bhattacharjee et al.
patent: 7118757 (2006-10-01), Seid et al.
patent: 2006/0029621 (2006-02-01), Granoff et al.
patent: 2007/0082014 (2007-04-01), Costantino
patent: 2008/0241180 (2008-10-01), Contorni
patent: 0011243 (1980-05-01), None
patent: WO 90/06696 (1990-06-01), None
patent: WO 98/58670 (1998-12-01), None
patent: WO-99/33488 (1999-07-01), None
patent: WO-99/61053 (1999-12-01), None
patent: WO-01/34642 (2001-05-01), None
patent: WO-02/09643 (2002-02-01), None
patent: WO-2004/019977 (2004-03-01), None
patent: WO-2005/004908 (2005-01-01), None
Costantino et al. Vaccine 10: 691-698, 1992.
Granoff et al. Vaccine 11: S46-S51, 1993.
van der Voort et al. Infect. immun. 64: 2745-2751, 1996.
Paradiso et al. Dev. Biol. Stand. 87: 269-275, 1996.
Corbel MJ. Biologicals 22: 353-360, 1994.
Wetzler LM. Ann. N.Y. Acad. Sci. 730: 367-370, 1994.
Glossary of Biochemistry and Molecular Biology. (Ed) Glick DM. Portland Press, London, p. 170, 1997.
Dalseg et al. Vaccines 96. (Ed) F. Brown. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., pp. 177-182, 1996.
Lowell et al. J. Exp. Med. 167: 658-663, 1988.
Poolman et al. Antonie van Leeuwenhoek 53: 413-419, 1987.
O'Hagan. J. Pharm. Pharmaco. 50: 1-10, Jan. 1998.
Granoff et al. Infect. Immun. 65: 1710-1715, May 1997.
Frasch CE. In: Development and Clinical Uses of Haemophilus B conjugate Vaccines. (Ed) Willis et al. M. Dekker, New York, pp. 435-453, 1994.
Vella et al. Biotechnology 20: 1-22, 1992.
Granoff et al. J. Pediatr. 121: 187-194, 1992.
Fukasawa et al. FEMS Immunol. Med. Microbiol. 41: 205-210, Jul. 1, 2004.
Lieberman et al., “Safety and Immunogenicity of a Serogroups A/CNeisseria meningitidisOligosaccharide-Protein Conjugate Vaccine in Young Children”JAMA275(19):1499-1503, May 15, 1996.
Milagres et al., “Antibody Studies in Mice of Outer Membrane Antigens for Use in an Improved Meningococcal B and C Vaccine”FEMS Immunology and Medical Microbiology13:9-17, 1996.
Debbag et al., “Evaluation of Adverse Reactions Associated to Antimeningococcal BC Vaccination in 16.700 Children”Clin. Infect. Dis. vol. 21, Sep. 1995, p. 790-A420.
Granoff et al., “MF59 Adjuvant Enhances Antibody Responses of Infant Baboons Immunized withHaemophilus influenzaeType b andNeisseria meningitidesGroup C Oligosaccharide-CRM197Conjugate Vaccine”Infection and Immunity65(5):1710-1715, May 1997.
Rosenqvist et al., “Effect of Aluminium Hydroxide and Meningococcal Serogroup C Capsular Polysaccharide on the Immunogenicity and Reactogenicity of a Group BNeisseria meningitidisOuter Membrane Vesicle Vaccine”Developments in Biological Standardization92:323-333, 1998.
Diaz Romero et al., “Current Status of Meningococcal Group B Vaccine Candidates: Capsular or non Capsular?”Clinical Microbiology Reviews7(4), Oct. 1994.
Rappuoli, Rino, et al., (1996) “New Vaccines, Especially New Combined Vaccines,” European Commission Cost/STD Initiative, Report of the Expert Panel VIII, Vaccine, 14: 691, 693-696.
“VA-MENGOC-BC,” Producet information from S.C.S. Farmacia Manes, Argentina.
International Preliminary Examination Report mailed Aug. 23, 2000, for international patent application No. PCT/US99/11977, filed May 28, 1999.
Bjune et al. (1991). “Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway,” Lancet 338(8775):1093-1096.
Fredriksen et al. (1991). “Production, characterization and control of MenB-vaccine “Folkehelsa”: an outer membrane vesicle vaccine against group B meningococcal disease,” NIPH Annals 14:67-79.
Katial et al. (2002). “Immunogenicity and Safety Testing of a Group B Intransal Meningococcal Native Outer Membrane Vesicle Vaccine,” Infection and Immunity 70(2):702-707.
Koeberling et al. (2007). “Improved immunogenicity of a H44/76 group B outer membrane vesicle vaccine with over-expressed genome-derived Neisserial antigen 1870,” Vaccine 25:1912-1920.
Peeters et al. (1996). “Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine,” Vaccine 14(10):1009-1015.

Affiliated with

Also associated with

Rating

Combination meningitidis B/C vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combination meningitidis B/C vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination meningitidis B/C vaccines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2649786